A Phase 1 interventional study of AZD7986, oral solution, 1 to 50 mg/mL and Placebo, oral solution in Safety, Pharmacokinetics, Pharmacodynamics, Food Effect, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females must be of non-, confirmed at screening by fulfilling one of the following criteria:
Male subjects must be non fertile, i.e., surgically sterilised with documentation of azoospermia or must practice an effective method to prevent pregnancies. Effective contraceptive methods are:
Exclusion Criteria:
Subject has increased risk of infection:
Some subjects lacking functional dipeptidyl peptidase 1 (DPP1) enzyme have been described to have periodontitis and palmoplantar hyperkeratosis:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
Drug: AZD7986, oral solution, 1 to 50 mg/mL
In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
Drug: Placebo, oral solution
Starting dose in single ascending dose part: 5 mg
Matching placebo
Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)
To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)
Time frame: Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD
To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD
To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD
To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD
To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD
To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD
To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD
To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD
To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD
To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD
To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD
To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD
To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD
To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD
To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD
To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD
To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD
To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD
To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD
To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD
To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD
To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD
To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD
To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD
To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD
To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD
To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2
Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD
To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2
Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker
Time frame: At Day 16, 21 ((last dosing day in Cohort 1), 25, 28 (last sampling day in Cohort 1 and last dosing day in Cohorts 2 and 3), 32, 38, 41 and 52
Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2
Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker
Time frame: At Day 12 (pre-dose, 6 hours and 12 hours)
This study was conducted at PAREXEL Early Phase Clinical Unit London, Level 7, Northwick Park Hospital in London. Healthy male and female participants were enrolled.
| Milestone | AZD7986 5 mg (Fasted State) - SAD | AZD7986 15 mg (Fasted State) - SAD | AZD7986 35 mg (Fasted State) - SAD | AZD7986 50 mg (Fasted State) - SAD | AZD7986 65 mg (Fasted State) - SAD | AZD7986 35 mg (Fed State) - SAD | AZD7986 10 mg - MAD | AZD7986 25 mg - MAD | AZD7986 40 mg - MAD | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 15 |
| Completed | 6 | 6 | 5 | 6 | 6 | 0 | 0 | 0 | 0 | 15 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | AZD7986 5 mg (Fasted State) - SAD | AZD7986 15 mg (Fasted State) - SAD | AZD7986 35 mg (Fasted State) - SAD | AZD7986 50 mg (Fasted State) - SAD | AZD7986 65 mg (Fasted State) - SAD | AZD7986 35 mg (Fed State) - SAD | AZD7986 10 mg - MAD | AZD7986 25 mg - MAD | AZD7986 40 mg - MAD | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | AZD7986 5 mg (Fasted State) - SAD | AZD7986 15 mg (Fasted State) - SAD | AZD7986 35 mg (Fasted State) - SAD | AZD7986 50 mg (Fasted State) - SAD | AZD7986 65 mg (Fasted State) - SAD | AZD7986 35 mg (Fed State) - SAD | AZD7986 10 mg - MAD | AZD7986 25 mg - MAD | AZD7986 40 mg - MAD | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 8 | 10 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 10 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)
| Participants | Part 1a (Fasted State) - Single Ascending Dose (SAD) | Part 1b (Fed State) - SAD | Part 2 - Multiple Ascending Dose (MAD) | Placebo - Part 1a (Fasted State)- SAD | Placebo - Part 1b (Fed State) - SAD | Placebo - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Any AE | 8 | 2 | 23 | 8 | 1 | 8 |
| Any AE with outcome = death | 0 | 0 | 0 | 0 | 0 | 0 |
| Any serious adverse event (SAE) (including death) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any AE leading to discontinuation of AZD7986 | 0 | 0 | 1 | 0 | 0 | 0 |
To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD
| h·nmol/L | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD | 839.0 ± 48.3 | 3855 ± 9.3 | 12430 ± 18.3 | 16470 ± 22.7 | 22880 ± 21.2 | 10790 ± 20.2 |
To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2
| h·nmol/L | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD | 1278 ± 18.9 | 3256 ± 15.9 | 6427 ± 31.0 | 5135 ± 49.4 | 14320 ± 39.5 | 29550 ± 53.5 |
To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.
| h·nmol/L | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD | 915.3 ± 46.1 | 4165 ± 10.8 | 13230 ± 19.6 | 17590 ± 25.2 | 24710 ± 21.5 | 11550 ± 22.6 |
To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data
| h·nmol/L | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD | 1778 ± 21.3 | 4957 ± 19.5 | 9866 ± 35.8 | 5565 ± 54.3 | 16660 ± 44.2 | 33220 ± 58.5 |
To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1
| h·nmol/L | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD | 1277 ± 18.9 | 3259 ± 15.9 | 6433 ± 31.0 | 2834 ± 35.1 | 7499 ± 27.4 | 15660 ± 43.3 |
To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve
| nmol/L | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD | 50.74 ± 47.2 | 202.3 ± 16.0 | 668.1 ± 26.7 | 1035 ± 11.5 | 1358 ± 24.2 | 434.8 ± 14.0 |
To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve
| nmol/L | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD | 138.6 ± 18.3 | 350.9 ± 19.3 | 672.0 ± 37.0 | 246.3 ± 26.2 | 598.1 ± 15.5 | 1235 ± 37.7 |
To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve
| Hour | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD | 0.50 ± 47.2 | 0.75 ± 16.0 | 0.75 ± 26.7 | 0.64 ± 11.5 | 0.75 ± 24.2 | 4.00 ± 14.0 |
To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve
| Hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD | 1.51 ± 21.3 | 0.75 ± 19.5 | 0.75 ± 35.8 | 1.50 (0.75 to 1.50) | 0.75 (0.52 to 2.00) | 1.12 (0.53 to 1.50) |
To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD
| Hour | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD | 19.96 ± 3.416 | 25.92 ± 4.452 | 23.80 ± 3.328 | 24.52 ± 5.836 | 25.50 ± 7.254 | 24.24 ± 4.259 |
To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data
| Hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD | 12.82 ± 1.477 | 14.85 ± 2.244 | 15.85 ± 4.132 | 25.85 ± 5.501 | 33.78 ± 10.31 | 30.04 ± 5.483 |
To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD
| Hour | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD | 27.03 ± 4.373 | 34.94 ± 5.863 | 32.15 ± 5.003 | 32.19 ± 8.360 | 33.76 ± 10.35 | 33.73 ± 6.429 |
To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2
| Hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD | 18.56 ± 2.245 | 21.84 ± 3.067 | 22.64 ± 5.844 | 33.73 ± 9.663 | 40.16 ± 10.58 | 37.46 ± 8.157 |
To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC
| Litre/Hour | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD | 14.23 ± 7.577 | 8.606 ± 0.9321 | 6.395 ± 1.281 | 6.938 ± 1.777 | 6.371 ± 1.317 | 7.363 ± 1.810 |
To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC
| Litre/Hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD | 13.61 ± 2.665 | 12.20 ± 2.485 | 10.24 ± 4.206 | 8.786 ± 2.772 | 8.165 ± 2.025 | 6.577 ± 2.867 |
To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
| Litre | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD | 385.1 ± 129.6 | 318.8 ± 46.72 | 215.8 ± 29.62 | 236.8 ± 39.64 | 231.0 ± 67.56 | 249.5 ± 24.96 |
To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
| Litre | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD | 248.9 ± 38.94 | 256.7 ± 36.11 | 222.7 ± 65.93 | 311.8 ± 56.96 | 393.2 ± 163.1 | 269.6 ± 79.13 |
To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1
| Ratio | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 2.257 ± 0.4560 | 2.330 ± 0.4828 | 2.476 ± 0.4521 |
To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1
| Ratio | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 1.799 ± 0.3084 | 1.667 ± 0.2007 | 1.881 ± 0.4015 |
To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%
| Ratio | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 1.610 ± 0.2539 | 1.535 ± 0.2479 | 1.599 ± 0.2082 |
To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
| nmol | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD | 1318 ± 348.5 | 4820 ± 1096 | 16530 ± 2145 | 19660 ± 4521 | 27770 ± 10200 | 18420 ± 2554 |
To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
| Percentage of dose excreted unchanged | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD | 11.09 ± 2.931 | 13.51 ± 3.074 | 19.86 ± 2.578 | 16.53 ± 3.802 | 17.97 ± 6.598 | 22.13 ± 3.069 |
To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)
| Liter/hour | AZD7986 5mg - Part 1a (Fasted State) - SAD | AZD7986 15mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 50mg - Part 1a (Fasted State) - SAD | AZD7986 65mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD | 1.734 ± 0.368 | 1.544 ± 0.2898 | 1.619 ± 0.2101 | 1.430 ± 0.1561 | 1.477 ± 0.5187 | 2.097 ± 0.1921 |
To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2
| nmol | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD | 2295 ± 638.1 | 5540 ± 1305 | 11390 ± 2415 | 4002 ± 1402 | 11960 ± 4665 | 24970 ± 8075 |
To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD
| h·nmol/L | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD | 12430 ± 18.3 | 10790 ± 20.2 |
To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.
| h·nmol/L | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD | 13230 ± 19.6 | 11550 ± 22.6 |
To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve
| nmol/L | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD | 668.1 ± 26.7 | 434.8 ± 14.0 |
To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve
| Hour | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD | 0.75 ± 26.7 | 4.00 ± 14.0 |
To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD
| Hour | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD | 23.80 ± 3.328 | 24.24 ± 4.259 |
To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD
| Hour | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD | 32.15 ± 5.003 | 33.73 ± 6.429 |
To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC
| Litre/Hour | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD | 6.395 ± 1.281 | 7.363 ± 1.810 |
To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz
| Litre | AZD7986 35mg - Part 1a (Fasted State) - SAD | AZD7986 35mg - Part 1b (Fed State) - SAD |
|---|---|---|
| Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD | 215.8 ± 29.62 | 249.5 ± 24.96 |
Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker
| Percentage change in NE activity | AZD7986 10mg - Part 2 - MAD | AZD7986 25mg - Part 2 - MAD | AZD7986 40mg - Part 2 - MAD | Placebo - Part 2 - MAD |
|---|---|---|---|---|
| Day 16 | -7.53 ± 11.59 | -28.25 ± 22.33 | -28.10 ± 16.87 | 7.39 ± 13.06 |
| Day 21 | -26.13 ± 3.116 | -36.73 ± 11.76 | -52.31 ± 14.90 | 1.39 ± 20.14 |
| Day 25 | -30.15 ± 8.412 | -40.06 ± 6.609 | -59.02 ± 11.77 | -5.15 ± 14.14 |
| Day 28 | -39.22 ± 9.141 | -45.05 ± 8.304 | -55.24 ± 9.087 | -16.36 ± 22.03 |
| Day 32 | NA ± NA | -53.35 ± 8.292 | -46.29 ± 37.55 | -6.216 ± 14.28 |
| Day 38 | NA ± NA | -54.42 ± 6.800 | -65.44 ± 7.556 | -19.51 ± 10.74 |
| Day 41 | NA ± NA | -53.46 ± 9.774 | -62.56 ± 8.324 | -18.14 ± 15.62 |
| Day 52 | NA ± NA | -17.73 ± 18.07 | -21.31 ± 18.07 | -20.98 ± 15.32 |
Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker
| 10^9 neutrophils/L | AZD7986 10mg - Part 2 - MAD | AZD7986 25mg - Part 2 - MAD | AZD7986 40mg - Part 2 - MAD | Placebo - Part 2 - MAD |
|---|---|---|---|---|
| Day 12, Pre-dose | 2.757 ± 0.4178 | 2.881 ± 0.5222 | 2.560 ± 0.9108 | 2.945 ± 0.7966 |
| Day 12, 6 h | NA ± NA | 3.401 ± 1.049 | 3.129 ± 0.7210 | 3.402 ± 1.178 |
| Day 12, 12 h | NA ± NA | 3.454 ± 0.7448 | 3.460 ± 0.5248 | 3.247 ± 0.7622 |
To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2
| Percentage of dose excreted unchanged | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD | 9.650 ± 2.683 | 9.319 ± 2.195 | 11.98 ± 2.539 | 16.83 ± 5.894 | 20.12 ± 7.847 | 26.25 ± 8.489 |
To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2
| Liter/hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD | 1.784 ± 0.4606 | 1.685 ± 0.3441 | 1.782 ± 0.3841 | NA ± NA | NA ± NA | NA ± NA |
To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2
| nmol | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 6525 ± 2684 | 18680 ± 8765 | 36160 ± 12030 |
To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2
| Percentage of dose excreted unchanged | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 27.44 ± 11.29 | 31.42 ± 14.74 | 38.01 ± 12.65 |
To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2
| Liter/hour | AZD7986 10mg - Day 1 - Part 2 - MAD | AZD7986 25mg - Day 1 - Part 2 - MAD | AZD7986 40mg - Day 1 - Part 2 - MAD | AZD7986 10mg - Day 21 - Part 2 - MAD | AZD7986 25mg - Day 28 - Part 2 - MAD | AZD7986 40mg - Day 28 - Part 2 - MAD |
|---|---|---|---|---|---|---|
| Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD | NA ± NA | NA ± NA | NA ± NA | 1.508 ± 0.438 | 1.618 ± 0.5085 | 1.527 ± 0.3418 |
Collected over Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1a (Fasted State) - Single Ascending Dose (SAD) | 0/30 (0%) | 0/30 (0%) | 8/30 (26.7%) |
| Part 1b (Fed State) - SAD | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part 2 - Multiple Ascending Dose (MAD) | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| Placebo - Part 1a (Fasted State)- SAD | 0/15 (0%) | 0/15 (0%) | 8/15 (53.3%) |
| Placebo - Part 1b (Fed State) - SAD | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Placebo - Part 2 - MAD | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Event | Part 1a (Fasted State) - Single Ascending Dose (SAD) | Part 1b (Fed State) - SAD | Part 2 - Multiple Ascending Dose (MAD) | Placebo - Part 1a (Fasted State)- SAD | Placebo - Part 1b (Fed State) - SAD | Placebo - Part 2 - MAD |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/30 | 2/5 | 6/24 | 2/15 | 0/3 | 1/12 |
| Gingival bleedingGastrointestinal disorders | 0/30 | 1/5 | 3/24 | 1/15 | 1/3 | 2/12 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/30 | 1/5 | 0/24 | 0/15 | 0/3 | 0/12 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/30 | 1/5 | 0/24 | 0/15 | 0/3 | 2/12 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/30 | 1/5 | 2/24 | 0/15 | 0/3 | 0/12 |
| ConstipationGastrointestinal disorders | 0/30 | 0/5 | 4/24 | 0/15 | 0/3 | 2/12 |
| DizzinessNervous system disorders | 1/30 | 0/5 | 2/24 | 1/15 | 0/3 | 2/12 |
| Feeling hotGeneral disorders | 0/30 | 0/5 | 0/24 | 0/15 | 0/3 | 2/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/30 | 0/5 | 3/24 | 1/15 | 0/3 | 2/12 |
| NasopharyngitisInfections and infestations | 1/30 | 0/5 | 3/24 | 0/15 | 0/3 | 1/12 |
| Age, Continuous(Years) | AZD7986 5 mg (Fasted State) - SAD | AZD7986 15 mg (Fasted State) - SAD | AZD7986 35 mg (Fasted State) - SAD | AZD7986 50 mg (Fasted State) - SAD | AZD7986 65 mg (Fasted State) - SAD | AZD7986 35 mg (Fed State) - SAD | AZD7986 10 mg - MAD | AZD7986 25 mg - MAD | AZD7986 40 mg - MAD | Placebo - Part 1a (Fasted) | Placebo - Part 1b (Fed State) | Placebo - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1a | 28.5 ± 5.39 | 29.7 ± 8.78 | 26.2 ± 3.66 | 32.2 ± 10.5 | 29.7 ± 6.65 | — | — | — | — | — | — | — | 29.2 ± 7.14 |
| Part 1b | — | — | — | — | — | 26.6 ± 3.91 | — | — | — | — | — | — | 26.6 ± 3.91 |
| Part 2 | — | — | — | — | — | — | 30.7 ± 5.65 | 38.4 ± 7.25 | 34.4 ± 9.17 | — | — | — | 34.8 ± 8.05 |
| Part 1a Placebo | — | — | — | — | — | — | — | — | — | 29.9 ± 7.24 | — | — | 29.9 ± 7.24 |
| Part 1b Placebo | — | — | — | — | — | — | — | — | — | — | 28.7 ± 8.5 | — | 28.7 ± 8.5 |
| Part 2 Placebo | — | — | — | — | — | — | — | — | — | — | — | 36.2 ± 7.2 | 36.2 ± 7.2 |
| Sex: Female, Male(Participants) | AZD7986 5 mg (Fasted State) - SAD | AZD7986 15 mg (Fasted State) - SAD | AZD7986 35 mg (Fasted State) - SAD | AZD7986 50 mg (Fasted State) - SAD | AZD7986 65 mg (Fasted State) - SAD | AZD7986 35 mg (Fed State) - SAD | AZD7986 10 mg - MAD | AZD7986 25 mg - MAD | AZD7986 40 mg - MAD | Placebo - Part 1a (Fasted) | Placebo - Part 1b (Fed State) | Placebo - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1a — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 1a — Male | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 45 |
| Part 1b — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 1b — Male | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 3 | 0 | 8 |
| Part 2 — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 2 — Male | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 8 | 10 | 0 | 0 | 12 | 36 |
Ran from Dec 2014 to primary completion in Aug 2016, 20 months.
Results were first posted in Dec 2018, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.